Study of the immune response in celiac patients with selective IgA deficiency who start a gluten-free diet.

Fecha de publicación: 13/03/2023 Fecha Ahead of Print: 01/03/2023

Autores de IIS La Fe

• Esther Donat Aliaga

  Autor

• Etna Masip Simó

  Autor

• Begoña Polo Miquel

  Autor

• 

  Carmen Ribes Koninckx

  Autor

• María Roca Llorens

  Autor

Participantes ajenos a IIS La Fe

• Giner-Perez, Lola
• Sinisterra-Sebastian, Paula
• Ballester, Veronica

Grupos

• Enfermedad celíaca e Inmunopatología digestiva

  

  Investigador Principal

  Carmen Ribes Koninckx

• Unidad Mixta De Investigación en Nutrición de Precisión para patologías digestivas (NUTRICURA PDig)

  

  Investigador Principal

  Carmen Ribes Koninckx

Abstract

Studies are scarce regarding IgG anti-tissue transglutaminase 2 (tTG) normalization in selective IgA deficient (SIgAD) celiac disease (CD) patients after beginning a gluten free diet (GFD). The aim of this study is to analyse the decreasing dynamics of IgG anti-tTG in patients diagnosed with CD who start a GFD. To achieve this objective, IgG and IgA anti-tTG levels at diagnosis and during follow-up in 11 SIgAD CD patients and in 20 IgA competent CD patients were retrospectively evaluated. At diagnosis, statistical differences were not found when comparing IgA anti-tTG levels of IgA competent subjects with IgG anti-tTG levels of SIgAD subjects. Regarding the decreasing dynamics, even though no statistical differences were found (p=0.06), normalization rates were slower for SIgAD CD patients. After 1 and 2years on GFD, respectively, only 18.2% and 36.3% of the SIgAD CD patients normalized IgG anti-tTG levels; otherwise, IgA anti-tTG reached values under the reference values in 30% and 80% of the IgA competent patients in the same time-points. Although IgG anti-tTG has demonstrated a high diagnostic efficiency in SIgAD CD pediatric patients, this test does not appear to be as precise for long-term GFD response monitoring as IgA anti-tTG levels in IgA sufficient patients.

© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Keywords

• Celiac disease; Selective IgA deficiency; Tissue transglutaminase; Anti-endomysium antibodies; Follow-up; Children